Zhaoke Oncology

China Oncology Focus Limited (COFL), often referred to as Zhaoke Oncology, is a clinical-stage biotechnology company and a subsidiary of Lee's Pharmaceutical Holdings. The company focuses on the development and commercialization of innovative oncology therapies, particularly for cancers with high prevalence in the Asian market. Its lead candidate is Socazolimab, an anti-PD-L1 monoclonal antibody currently in late-stage clinical trials for multiple indications including biliary tract cancer and lymphoma. COFL maintains a diverse pipeline that includes immune checkpoint inhibitors, oncolytic viruses, and targeted small molecules, leveraging both internal R&D and strategic in-licensing partnerships.